-
1
-
-
74949133978
-
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
-
19917871 10.1200/JCO.2009.23.5622 1:CAS:528:DC%2BC3cXht1agsbs%3D
-
Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266
-
(2009)
J Clin Oncol
, vol.27
, pp. 6251-6266
-
-
Azzoli, C.G.1
Baker, Jr.S.2
Temin, S.3
Pao, W.4
Aliff, T.5
Brahmer, J.6
Johnson, D.H.7
Laskin, J.L.8
Masters, G.9
Milton, D.10
Nordquist, L.11
Pfister, D.G.12
Piantadosi, S.13
Schiller, J.H.14
Smith, R.15
Smith, T.J.16
Strawn, J.R.17
Trent, D.18
Giaccone, G.19
-
2
-
-
56249109644
-
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
-
19027483 10.1016/S0140-6736(08)61758-4 1:CAS:528:DC%2BD1cXhsVWhtbjM
-
Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809-1818
-
(2008)
Lancet
, vol.372
, pp. 1809-1818
-
-
Kim, E.S.1
Hirsh, V.2
Mok, T.3
Socinski, M.A.4
Gervais, R.5
Wu, Y.L.6
Li, L.Y.7
Watkins, C.L.8
Sellers, M.V.9
Lowe, E.S.10
Sun, Y.11
Liao, M.L.12
Osterlind, K.13
Reck, M.14
Armour, A.A.15
Shepherd, F.A.16
Lippman, S.M.17
Douillard, J.Y.18
-
3
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
16014882 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
Tan, E.H.4
Hirsh, V.5
Thongprasert, S.6
Campos, D.7
Maoleekoonpiroj, S.8
Smylie, M.9
Martins, R.10
Van Kooten, M.11
Dediu, M.12
Findlay, B.13
Tu, D.14
Johnston, D.15
Bezjak, A.16
Clark, G.17
Santabárbara, P.18
Seymour, L.19
-
4
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
15118073 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
Haber, D.A.14
-
5
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D
-
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Jänne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
Fujii, Y.13
Eck, M.J.14
Sellers, W.R.15
Johnson, B.E.16
Meyerson, M.17
-
6
-
-
33748429730
-
Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer
-
17409862
-
Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I, Gazdar A, Wistuba I (2006) Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 1:231-239
-
(2006)
J Thorac Oncol
, vol.1
, pp. 231-239
-
-
Tsao, A.S.1
Tang, X.M.2
Sabloff, B.3
Xiao, L.4
Shigematsu, H.5
Roth, J.6
Spitz, M.7
Hong, W.K.8
Gazdar, A.9
Wistuba, I.10
Gazdar, A.11
Wistuba, I.12
-
7
-
-
33745928129
-
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21
-
16800964 10.3816/CLC.2006.n.022 1:CAS:528:DC%2BD28XmsFyqt7c%3D
-
Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L, Shepherd FA (2006) Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 7:389-394
-
(2006)
Clin Lung Cancer
, vol.7
, pp. 389-394
-
-
Clark, G.M.1
Zborowski, D.M.2
Santabarbara, P.3
Ding, K.4
Whitehead, M.5
Seymour, L.6
Shepherd, F.A.7
-
8
-
-
77953541527
-
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
-
20493771 10.1016/S1470-2045(10)70112-1 1:CAS:528:DC%2BC3cXntVCksb0%3D
-
Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529
-
(2010)
Lancet Oncol
, vol.11
, pp. 521-529
-
-
Cappuzzo, F.1
Ciuleanu, T.2
Stelmakh, L.3
Cicenas, S.4
Szczésna, A.5
Juhász, E.6
Esteban, E.7
Molinier, O.8
Brugger, W.9
Melezínek, I.10
Klingelschmitt, G.11
Klughammer, B.12
Giaccone, G.13
-
9
-
-
64249099411
-
-
American Joint Committee on Cancer 7 Springer New York
-
American Joint Committee on Cancer (2010) AJCC cancer staging manual, 7th edn. Springer, New York
-
(2010)
AJCC Cancer Staging Manual
-
-
-
10
-
-
57849117384
-
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
-
19097774 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D
-
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
Schwartz, L.H.4
Sargent, D.5
Ford, R.6
Dancey, J.7
Arbuck, S.8
Gwyther, S.9
Mooney, M.10
Rubinstein, L.11
Shankar, L.12
Dodd, L.13
Kaplan, R.14
Lacombe, D.15
Verweij, J.16
-
11
-
-
77958179944
-
Erlotinib in advanced non-small cell lung cancer: Efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
-
20736854 10.1097/JTO.0b013e3181f1c7b0
-
Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M, Heigener D (2010) Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 5:1616-1622
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1616-1622
-
-
Reck, M.1
Van Zandwijk, N.2
Gridelli, C.3
Baliko, Z.4
Rischin, D.5
Allan, S.6
Krzakowski, M.7
Heigener, D.8
-
12
-
-
82955229588
-
Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients
-
22058419 10.1093/jjco/hyr159
-
Hata A, Katakami N, Kunimasa K, Yoshioka H, Fujita S, Kaji R, Tachikawa R, Tomii K, Imai Y, Iwasaku M, Ishida T (2011) Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients. Jpn J Clin Oncol 41:1366-1372
-
(2011)
Jpn J Clin Oncol
, vol.41
, pp. 1366-1372
-
-
Hata, A.1
Katakami, N.2
Kunimasa, K.3
Yoshioka, H.4
Fujita, S.5
Kaji, R.6
Tachikawa, R.7
Tomii, K.8
Imai, Y.9
Iwasaku, M.10
Ishida, T.11
-
13
-
-
69549116582
-
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: A multicenter trial by the Korean Cancer Study Group
-
19687764 10.1097/JTO.0b013e3181b270a7
-
Uhm JE, Park BB, Ahn MJ, Lee J, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Park K (2009) Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. J Thorac Oncol 4:1136-1143
-
(2009)
J Thorac Oncol
, vol.4
, pp. 1136-1143
-
-
Uhm, J.E.1
Park, B.B.2
Ahn, M.J.3
Lee, J.4
Ahn, J.S.5
Kim, S.W.6
Kim, H.T.7
Lee, J.S.8
Kang, J.H.9
Cho, J.Y.10
Song, H.S.11
Park, S.H.12
Sohn, C.H.13
Shin, S.W.14
Choi, J.H.15
Park, K.16
-
14
-
-
79954741752
-
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports
-
21272159 10.1111/j.1349-7006.2011.01887.x 1:CAS:528:DC%2BC3MXhsFehsLfP
-
Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Takahashi K, Yamamoto N (2011) Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 102:1032-1037
-
(2011)
Cancer Sci
, vol.102
, pp. 1032-1037
-
-
Shukuya, T.1
Takahashi, T.2
Kaira, R.3
Ono, A.4
Nakamura, Y.5
Tsuya, A.6
Kenmotsu, H.7
Naito, T.8
Kaira, K.9
Murakami, H.10
Endo, M.11
Takahashi, K.12
Yamamoto, N.13
-
15
-
-
20044364940
-
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
-
10.1093/jnci/dji055 1:CAS:528:DC%2BD2MXitV2jsb4%3D
-
Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Nati Cancer Inst 97:339-346
-
(2005)
J Nati Cancer Inst
, vol.97
, pp. 339-346
-
-
Shigematsu, H.1
Lin, L.2
Takahashi, T.3
Nomura, M.4
Suzuki, M.5
Wistuba, I.I.6
Fong, K.M.7
Lee, H.8
Toyooka, S.9
Shimizu, N.10
Fujisawa, T.11
Feng, Z.12
Roth, J.A.13
Herz, J.14
Minna, J.D.15
Gazdar, A.F.16
-
16
-
-
79952232123
-
Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma
-
21318227 1:CAS:528:DC%2BC3MXksFWltL4%3D
-
Miyamae Y, Shimizu K, Hirato J, Araki T, Tanaka K, Ogawa H, Kakegawa S, Sugano M, Nakano T, Mitani Y, Kaira K, Takeyoshi I (2011) Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep 25:921-928
-
(2011)
Oncol Rep
, vol.25
, pp. 921-928
-
-
Miyamae, Y.1
Shimizu, K.2
Hirato, J.3
Araki, T.4
Tanaka, K.5
Ogawa, H.6
Kakegawa, S.7
Sugano, M.8
Nakano, T.9
Mitani, Y.10
Kaira, K.11
Takeyoshi, I.12
-
17
-
-
84862778728
-
Retrospective study of erlotinib in patients with advanced squamous lung cancer
-
22420950 10.1016/j.lungcan.2012.02.012
-
Tseng JS, Yang TY, Chen KC, Hsu KH, Chen HY, Chang GC (2012) Retrospective study of erlotinib in patients with advanced squamous lung cancer. Lung Cancer 77:128-133
-
(2012)
Lung Cancer
, vol.77
, pp. 128-133
-
-
Tseng, J.S.1
Yang, T.Y.2
Chen, K.C.3
Hsu, K.H.4
Chen, H.Y.5
Chang, G.C.6
-
18
-
-
76149100579
-
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705
-
19898258 10.1097/JTO.0b013e3181c20063
-
Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M (2010) A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol 5:99-104
-
(2010)
J Thorac Oncol
, vol.5
, pp. 99-104
-
-
Yoshioka, H.1
Hotta, K.2
Kiura, K.3
Takigawa, N.4
Hayashi, H.5
Harita, S.6
Kuyama, S.7
Segawa, Y.8
Kamei, H.9
Umemura, S.10
Bessho, A.11
Tabata, M.12
Tanimoto, M.13
-
19
-
-
24944440830
-
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
-
16043829 10.1200/JCO.2005.02.840 1:CAS:528:DC%2BD2MXhtVKgtbzN
-
Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899
-
(2005)
J Clin Oncol
, vol.23
, pp. 5892-5899
-
-
Herbst, R.S.1
Prager, D.2
Hermann, R.3
Fehrenbacher, L.4
Johnson, B.E.5
Sandler, A.6
Kris, M.G.7
Tran, H.T.8
Klein, P.9
Li, X.10
Ramies, D.11
Johnson, D.H.12
Miller, V.A.13
-
20
-
-
77951880386
-
Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: A comprehensive analysis of 26,957 patients with NSCLC
-
20354456
-
Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, Saito R, Maruyama Y, Kawahara M, Ignatius Ou SH (2010) Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 5:620-630
-
(2010)
J Thorac Oncol
, vol.5
, pp. 620-630
-
-
Kawaguchi, T.1
Takada, M.2
Kubo, A.3
Matsumura, A.4
Fukai, S.5
Tamura, A.6
Saito, R.7
Maruyama, Y.8
Kawahara, M.9
Ignatius Ou, S.H.10
-
21
-
-
33646238486
-
Effects of smoking on the pharmacokinetics of erlotinib
-
16609030 10.1158/1078-0432.CCR-05-2235 1:CAS:528:DC%2BD28XjtlChs7w%3D
-
Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ (2006) Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 12:2166-2171
-
(2006)
Clin Cancer Res
, vol.12
, pp. 2166-2171
-
-
Hamilton, M.1
Wolf, J.L.2
Rusk, J.3
Beard, S.E.4
Clark, G.M.5
Witt, K.6
Cagnoni, P.J.7
-
22
-
-
84861775939
-
New strategies in squamous cell carcinoma of the lung: Identification of tumor drivers to personalize therapy
-
22461458 10.1158/1078-0432.CCR-11-2055 1:CAS:528:DC%2BC38XnvVOgt7o%3D
-
Gold KA, Wistuba II, Kim ES (2012) New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res 18:3002-3007
-
(2012)
Clin Cancer Res
, vol.18
, pp. 3002-3007
-
-
Gold, K.A.1
Wistuba, I.I.2
Kim, E.S.3
|